Eli Lilly and Company & Goldman Sachs

Eli Lilly and Company: Eli Lilly has a strategic collaboration with Scribe, which may benefit from Scribe's successful IPO and pipeline progress.

Goldman Sachs: Goldman Sachs served as a joint book-running manager, benefiting from the successful offering.

Eli Lilly and Company: Eli Lilly is the acquirer, paying $2.8B upfront for Atai Life Sciences to bolster its neuroscience pipeline and diversify beyond its weight-loss drug franchise. The deal is part of a broader acquisition spree funded by strong commercial performance.

Goldman Sachs: Goldman Sachs acted as exclusive financial advisor to Eli Lilly in the acquisition.

Eli Lilly and Company: Eli Lilly's stock jumped after a committee of the European Medicines Agency recommended one of its medicines for approval, boosting its market performance.

Goldman Sachs: Rose after beating earnings expectations.

Eli Lilly and Company: Eli Lilly is an employer involved in the RaiseMe project, contributing to the nonprofit's goal of adapting the workforce to an AI economy.

Goldman Sachs: Goldman Sachs released an estimate that a quarter of U.S. work hours could be automated by AI, highlighting the potential scale of workforce disruption.

Eli Lilly and Company: Eli Lilly and Company is mentioned as one of the companies that SpaceX's valuation will surpass, emphasizing the magnitude of SpaceX's market entry.

Goldman Sachs: Goldman Sachs was a lead banker in the SpaceX IPO, playing a crucial role in the offering and benefiting from the associated fees.